Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002985:Clinical Protocols; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000627:therapeutic use*; D008224:Lymphoma, Follicular / Q000628:therapy*; D018579:Patient Selection; D012074:Remission Induction
D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes; D016178:Granulocyte-Macrophage Colony-Stimulating Factor